Dr. Green is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Virginia Medical CenterResidency, Internal Medicine, 1995 - 1998
University of Texas Medical Branch School of MedicineClass of 1995
Certifications & Licensure
TX State Medical License 2000 - 2026
MA State Medical License 1981 - 2017
Clinical Trials
- CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer Start of enrollment: 2005 Dec 01
Publications & Presentations
PubMed
- 98 citationsResection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcomeDaniel E. Abbott, Antoine Brouquet, Elizabeth A. Mittendorf, Andreas Andreou, Funda Meric-Bernstam
Surgery. 2012-05-01 - 3170 citationsTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe C. Yuen
Nature. 2018-02-22 - 381 citationsTrastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of f...Véronique Diéras, David Miles, Sunil Verma, Mark D. Pegram, Manfred Welslau
The Lancet. Oncology. 2017-06-01
Press Mentions
Moderna and MSD Begin Trial of mRNA-4157 and Keytruda Combination for Lung CancerOctober 29th, 2024- Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 TrialSeptember 17th, 2024
- Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 TrialSeptember 7th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
